Clinician-patient Interaction During Addiction Consultation (CLiPID)
|ClinicalTrials.gov Identifier: NCT01769651|
Recruitment Status : Unknown
Verified February 2015 by Prof G Humphris, University of St Andrews.
Recruitment status was: Not yet recruiting
First Posted : January 17, 2013
Last Update Posted : February 18, 2015
Accurately predicting the risk factors of patients' suffering a drug overdose plays a crucial role in effective prevention of drug overdose. In order to investigate possible risk factors for drug overdose, the NHS Fife Research & Development Office funded this project to be carried out by a group of researchers based in the University of St Andrews, in collaboration with the NHS Fife Addiction Services.
To improve our understanding of drug misusers' risk of suffering a drug overdose, the investigators focus on the factors that are associated with the aspects of the addiction consultation process (e.g. verbal and non-verbal behaviours of clinicians and patients). The investigators are particularly interested in how clinicians recognize and manage patients' emotional concerns during consultations. Based on the empirical evidence in the area of patient-centred consultation, the investigators hypothesize that successful management of patient emotional distress is positively correlated with improved healthcare outcomes including patient's feeling more emotionally valued and satisfied with the consultation. The investigators also hypothesize, according to the research findings on the relationship between facial expressions and suicidal reattempt, that some non-verbal behaviours during consultation (e.g. patient's 'looking down' activity) are related to patient's risk of suffering a drug overdose.
After obtaining informed consent from clinicians and patients, the investigators will video record a patient's first consultation session with a key worker within the NHS Fife Addition Services. The investigators expect to collect a minimum of 16 consultations (about eight clinicians with two patients per staff member) for this one-year pilot study. A validated coding scheme will be modified to code patients' expressions of emotional distress and clinicians' responses. Additional survey method will be also employed to collect demographic information and patient satisfaction. The investigators hope the findings of the study will improve our understanding of drug overdose risk factors and contribute to the development of drug overdose prevention programmes.
|Condition or disease||Intervention/treatment|
|Drug Dependency||Other: methadone replacement therapy|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||16 participants|
|Official Title:||Clinician-patient Interaction During Addiction Consultation and Drug Overdose Risk|
|Study Start Date :||March 2015|
|Estimated Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||December 2015|
Drug service users
Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
Other: methadone replacement therapy
Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
- Number of days patients injected non-prescribed drugs [ Time Frame: one month after the video recorded consultation ]The primary outcome measure of the study is patient risk of suffering a drug overdose, measured by the number of days patients injected non-prescribed drugs, recorded on the Treatment Outcomes Profile Questionnaire, one month after the recorded consultation.
- Patient Satisfaction [ Time Frame: an expected average of 30 minutes after recorded consultation ]Patient satisfaction is the secondary outcome, measured by the Patient Satisfaction Survey completed by patients, an expected average of 30 minutes after the recorded consultation.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01769651
|Contact: Yuefang Zhou, PhDemail@example.com|
|School of Medicine, University of St Andrews|
|St Andrews, Fife, Scotland, United Kingdom, KY16 9TF|
|Principal Investigator:||Gerry M Humphris, PhD||University of St Andrews|